In addition, certain hypoglycemic agents show promise in the treatment of MASLD, including peroxisome proliferator–activated receptor (PPAR) agonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide–1 receptor (GLP-1R) agonists (6). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.